A recent report showed that enhanced SIRT1 expression in a β-catenin-dependent mouse model of colon cancer inhibited intestinal-tumor formation, thereby indicating that the effects of SIRT1 might vary in different tumor models, and depend on the presence of appropriate downstream targets [73]. Here, SIRT1 is linked to malignant colon neoplasm.